LS9 Selected as a Top 10 Venture-Backed Green Company by The Wall Street Journal

LS9 Selected as a Top 10 Venture-Backed Green Company by The Wall Street Journal

October 19, 2012

(GLOBE NEWSWIRE) -- LS9, Inc., a technology leader in the development of renewable and sustainable chemicals and fuels, today announced that the The Wall Street Journal selected the Company as one of the 2012 Top 10 Venture-Backed Green Companies.

BG Medicine, Inc. Appoints Charles H. Abdalian, Jr. as Chief Financial Officer

BG Medicine, Inc. Appoints Charles H. Abdalian, Jr. as Chief Financial Officer

October 18, 2012

WALTHAM, Mass., Oct. 18, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that it has appointed Charles H. Abdalian, Jr., as the company's Executive Vice President, Chief Financial Officer. Mr.

Joule, LS9 and Novomer Named to the Global Cleantech 100 2012

Joule, LS9 and Novomer Named to the Global Cleantech 100 2012

October 17, 2012

Welcome to the Global Cleantech 100 2012

The Global Cleantech 100 represents innovation and highlights the companies most likely to make a significant market impact in the next 5-10 years

The OCS™ Lung Initial European Clinical Experience Featured in The Lancet

The OCS™ Lung Initial European Clinical Experience Featured in The Lancet

October 10, 2012

Andover, Mass., October 10, 2012, The Lancet has published the initial series of successful lung transplants demonstrating the feasibility and safety of using the Organ Care System™ (OCS™) Lung technology, at Hannover Medical Schoo

Keraflex® Keratoconus Treatment Study Begins in US

Keraflex® Keratoconus Treatment Study Begins in US

October 11, 2012

Hersh Vision Group is the first to offer this novel keratoconus treatment

Life Sciences Venture Funding Drops

Life Sciences Venture Funding Drops

October 5, 2012

In today’s economy, capital is much more difficult to raise, and the various sources of investment, from private angels to larger VC firms, are understandably much more cautious and conservative about where they place their money. “The economic recession made its impact on life sciences investments, as there have been negative returns on investments for the last 12 years.

LS9 Scales Up in Chemical Business As Biofuels Industry Re-Tools

LS9 Scales Up in Chemical Business As Biofuels Industry Re-Tools

October 4, 2012

The South San Francisco company LS9 recently produced five tons of industrial chemicals from plant sugars at a Florida demonstration facility, a step toward proving that its genetically engineered microbes can manufacture carbon compounds and fuels at a commercial scale.

T2 Biosystems Named a "Fierce 15" Medical Device and Diagnostic Company of 2012

T2 Biosystems Named a "Fierce 15" Medical Device and Diagnostic Company of 2012

October 2, 2012

LEXINGTON, Mass., Oct 02, 2012 (BUSINESS WIRE) -- T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced that it has been named to the FierceMedicalDevices "Fierce 15" list, designating it as one of the leading medical device and diagnostic companies of 2012.

Shire scoops up Pervasis Therapeutics

Shire scoops up Pervasis Therapeutics

April 12, 2012

By Galen Moore, Boston Business Journal

The Wall Street Journal Names Acceleron to "The Next Big Thing" List of Top 50 Start-Ups in the United States

The Wall Street Journal Names Acceleron to "The Next Big Thing" List of Top 50 Start-Ups in the United States

September 27, 2012

Acceleron one of only two biopharmaceutical companies to make the list